Finance

Beta
Ask
Lists
003220:KRX
Daewon Pharmaceutical Co Ltd
â‚©9,240.00
0.00%
(0.00) 1D
Jun 12, 3:30:20 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 003220...
Open
â‚©9,310
High
â‚©9,510
Low
â‚©9,160
Mkt. cap
207.23B
Avg. vol.
209.14K
Volume
0.00
Dividend
2.71%
Quarterly dividend
â‚©62
Ex-dividend date
Dec 29, 2025
52-wk high
â‚©14,090
52-wk low
â‚©8,070
EPS
-â‚©206
Shares outstanding
22.43M
No. of employees
1K
Open
â‚©9,310
High
â‚©9,510
Low
â‚©9,160
Mkt. cap
207.23B
Avg. vol.
209.14K
Volume
0.00
Dividend
2.71%
Quarterly dividend
â‚©62
Ex-dividend date
Dec 29, 2025
52-wk high
â‚©14,090
52-wk low
â‚©8,070
EPS
-â‚©206
Shares outstanding
22.43M
No. of employees
1K
News stories
From sources across the web
About Daewon Pharmaceutical Co Ltd
CEOBaek Seung-ho | Baek Seung-yeol
Employees1.28K
Founded1958
Headquarters-
SectorPharmaceutical industry
Websitedaewonpharm.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
143.86B
143.94B
159.81B
158.06B
Cost of goods sold
80.82B
83.20B
86.55B
83.32B
Cost of revenue
80.82B
83.20B
86.55B
83.32B
Research and development expenses
5.62B
6.44B
6.55B
6.78B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
56.38B
61.82B
58.27B
60.97B
Operating expense
64.44B
71.13B
67.39B
70.35B
Total operating expenses
145.26B
154.33B
153.93B
153.67B
Operating income
-1.41B
-10.39B
5.88B
4.38B
Other non operating income
630.35M
-1.24B
-2.49B
127.02M
EBT including unusual items
-3.32B
-12.01B
11.79B
3.92B
EBT excluding unusual items
-3.47B
-11.95B
2.77B
4.15B
Income tax expense
9.11M
6.02B
-2.45B
1.83B
Effective tax rate
-0.27%
-50.14%
-20.77%
46.72%
Other operating expenses
762.10M
890.07M
847.43M
869.07M
Net income
-2.98B
-17.41B
13.60B
2.42B
Net profit margin
-2.07%
-12.10%
8.51%
1.53%
Earnings per share
-
-
-
-
Interest and investment income
382.20M
150.63M
346.40M
449.07M
Interest expense
-2.05B
-1.98B
-1.40B
-1.74B
Net interest expenses
-1.67B
-1.82B
-1.06B
-1.29B
Depreciation and amortization charges
1.33B
1.15B
1.06B
1.05B
EBITDA
4.74B
-4.51B
11.94B
10.76B
Gain or loss from assets sale
250.40M
-197.23M
1.85B
4.90M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer